Literature DB >> 2369087

Carcinoembryonic antigen, CA 19-9 and CA 50 in monitoring human squamous cell carcinoma of the esophagus.

E Munck-Wikland1, R Kuylenstierna, J Lindholm, B Wahren.   

Abstract

The serum levels of Carcinoembryonic antigen, CA 19-9 and CA 50 were assessed in 60 patients with squamous cell carcinoma of the esophagus during the course of the disease. In 53 patients, the effect of preoperative or final treatment on tumor marker levels could be analysed, and the change in tumor marker levels discriminated significantly the patients who showed tumor mass/symptom regress from the patients who displayed progress or undecided change. Progress later in the course of the disease was reflected by a statistically significant increase in all three tumor marker assays, and in 8/18 (44%) patients the tumor marker increase was seen prior to other signs of tumor progression. The appearance of distant metastases was associated (11/12) with increase in CEA levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369087

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients.

Authors:  Shin-ichi Kosugi; Tadashi Nishimaki; Tatsuo Kanda; Satoru Nakagawa; Manabu Ohashi; Katsuyoshi Hatakeyama
Journal:  World J Surg       Date:  2004-06-04       Impact factor: 3.352

2.  Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis).

Authors:  Bhawna Bagaria; Sadhna Sood; Rameshwaram Sharma; Soniya Lalwani
Journal:  Cancer Biol Med       Date:  2013-09       Impact factor: 4.248

3.  Prognostic significance of serum carcinoembryonic antigen and squamous cell carcinoma antigen in patients with esophageal squamous cell carcinoma undergoing radical esophagectomy.

Authors:  Jia Hu; Pengpeng Kuang; Dongni Chen; Youfang Chen; Zhesheng Wen
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.